Bayer's New Precision Therapy for Liver Cancer Emerges

German pharmaceutical company Bayer has launched the global Phase 1 clinical trial (BANTAM-01) of 'BAY 3547926', a targeted alpha therapy (TAT) candidate that targets the GPC3 (Glypican-3) protein, marking its entry into the next-generation anticancer drug market. This trial will evaluate the safety, tolerability, and preliminary efficacy of the drug in patients with GPC3-positive advanced hepatocellular carcinoma (HCC). GPC3 is a target that is rarely expressed in normal adult tissues but is overexpressed in 70-75% of advanced liver cancer cells, which is expected to maximize the selective cancer cell killing effect. Bayer aims to overcome the side effects of existing systemic chemotherapy and establish a new paradigm for precision medicine in liver cancer, an area with high unmet medical needs.

Powerful Cell-Killing Mechanism Utilizing Actinium-225

The key strength of this therapy lies in its use of the potent radioactive isotope actinium-225 (225Ac) conjugated to a monoclonal antibody (mAb) to directly deliver it to cancer cells. The alpha particles emitted by actinium-225 have a short penetration range of only a few tens of micrometers (µm), but they carry a high amount of energy, which physically destroys the double-helix DNA of target cancer cells, inducing potent cell death while minimizing damage to normal tissues. Bayer is employing a theranostics strategy by pre-administering a non-radioactive antibody conjugate, BAY 3547922, to block non-target binding and co-administering a selective imaging agent, BAY 3713391. This precise approach provides a mechanistic differentiation that can significantly reduce systemic toxicity and dramatically improve patient tolerability.

Market Leadership Strategy Through Multi-faceted Clinical Design

The BANTAM-01 trial consists of a total of four stages, and after determining the safe and active dose of the stand-alone therapy, it will evaluate the scalability of combination therapy with other standard treatments, such as immune checkpoint inhibitors. The Phase 1 trial is being conducted in multiple countries, including the United States, Canada, Belgium, Finland, France, Spain, the United Kingdom, and China, and is designed to enroll approximately 148 patients. The data accumulated during the dose escalation phase will serve as a key platform for diversifying future development directions, reflecting Bayer's commercial roadmap to move beyond single-agent therapy and establish a foothold in the combination therapy market. The objective response rate (ORR) and progression-free survival (PFS) data to be obtained by the primary completion date of July 2029 will be a major milestone in determining the success of Bayer's radiopharmaceutical pipeline.

Fierce Competition for Dominance in the Rapidly Growing Alpha Therapy Market

The global hepatocellular carcinoma treatment market is projected to grow rapidly to a high-value market of $12.87 billion to $33 billion by 2033-2035. As there are currently no approved GPC3-targeted therapies, Bayer is engaged in fierce competition with companies such as RayzeBio, a subsidiary of BMS, which is developing the peptide-based actinium therapy 'RYZ801' (Phase 1 trial), and AstraZeneca, which is developing the T-cell engager 'AZD9793'. Bayer plans to leverage its radiopharmaceutical capabilities, which were established through the acquisition of Noria and PSMA Therapeutics in 2021, to demonstrate the superiority of its antibody-based platform, which has a longer half-life compared to peptides. If this trial is successfully completed, it could become a powerful first-in-class innovative drug that will change the landscape of advanced liver cancer treatment, a highly challenging area with significant unmet needs.